- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04382729
Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia
Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This prospective, randomized, controlled, parallel-group, single-blind trial will include 80 patients who had undergone mechanical or non-invasive ventilation following pneumonia-induced respiratory failure. Patients are randomized to a control group (routine physical therapy for 3 weeks) or a NMES group (routine physical therapy plus NMES of quadriceps and gastrocnemius muscles for 3 weeks). The primary outcome is physical performance assessed through the Short Physical Performance Battery (SPPB). Secondary outcomes include independence level, perceived fatigue, muscle strength, rectus femoris thickness, and walking performance. The SPBB and walking performance will be assessed once (after the 3-week intervention period), while all other outcomes will be assessed twice (before and after the intervention).
NMES is a simple and non-invasive technique for muscle strengthening that is usually well tolerated, does not produce adverse effects, requires no or little cooperation from patients and is quite inexpensive. Therefore, proving the effectiveness of NMES therapy for physical and muscle function in COVID-19 patients could support its systematic incorporation in post-ICU rehabilitation protocols of patients presenting with post-intensive care syndrome.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marco Alessandro Minetto, MD, PhD
- Phone Number: +39 011 6705472
- Email: marco.minetto@unito.it
Study Contact Backup
- Name: Chiara Busso, MD
- Phone Number: +39 011 6705472
- Email: chiara.busso@unito.it
Study Locations
-
-
TO
-
Orbassano, TO, Italy, 10043
- Recruiting
- San Luigi Gonzaga Hospital
-
Contact:
- Federica Gamna, MD
- Phone Number: +39 0119026994
- Email: f.gamna@sanluigi.piemonte.it
-
Contact:
- Sabrina Dal Fior, MD
- Phone Number: +39 0119026994
- Email: s.dalfior@sanluigi.piemonte.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age above 18 years
- respiratory (PaO2/FiO2 ratio > 180 mmHg) and hemodynamic stability for at least two days after withdrawal of mechanical ventilation and neuromuscular blocking agents
Exclusion Criteria:
- pregnancy
- known or suspected malignancy in the lower limbs
- body mass index equal or greater than 35 kg/m2
- conditions preventing NMES treatment (e.g., deep vein thrombosis, skin lesions, rhabdomyolysis)
- conditions preventing the outcome assessment (e.g., amputation or inability to transfer independently from bed to chair before hospital admission)
- presence of an implanted cardiac pacemaker or defibrillator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Group
|
The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists.
It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
|
Experimental: NMES Group
|
The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks).
NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles.
The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs).
Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle.
The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week.
Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short Physical Performance Battery (SPPB) Score
Time Frame: 1 week after the intervention
|
The SPPB score is a composite measure assessing standing balance (ability to stand for up to 10 seconds with feet positioned in three ways: together side-by-side, semi-tandem and tandem), walking speed (time to complete a 4-m walk), and sit-to- stand performance (time to rise from a chair five times).
Each task is scored out of 4 points, with the scores from the three tests summed up to give a total, with a maximum of 12 points and a minimum of 0.
|
1 week after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Independence Measure (FIM) Scale Score
Time Frame: Before and 1 week after the intervention
|
The FIM is an 18-item, clinician-reported scale that assesses function in six areas including self-care, continence, mobility, transfers, communication, and cognition.
Each of the 18 items is graded on a scale of 1-7 based on level of independence in that item (1 = total assistance required, 7 = complete independence)
|
Before and 1 week after the intervention
|
Fatigue Severity Scale Score
Time Frame: Before and 1 week after the intervention
|
The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle
|
Before and 1 week after the intervention
|
Muscle Strength
Time Frame: Before and 1 week after the intervention
|
Handgrip strength is assessed for both sides using a handheld device.
Patients are instructed to perform a maximal voluntary isometric contraction by contracting their muscles as forcefully as possible for 4-5 s.
The test is repeated three times for each side and the highest value is retained.
Lower limb strength is assessed as the sum of knee extension and plantar flexion strength of both sides.
Muscle strength is rated using the Medical Research Council (MRC) scale that ranges from 0 (no muscle contraction) to 5 (normal resistance), for a maximum score of 20 points.
|
Before and 1 week after the intervention
|
Two Step Test Length
Time Frame: 1 week after the intervention
|
Subjects are required to step out with the dominant leg maximally, then to step out with the other leg maximally, and then to draw and match the first leg to the second leg while maintaining body stability with either supporting leg.
The distance between the start line and the tiptoe of the second step foot is measured as the double step length (sum of the first and second steps).
|
1 week after the intervention
|
Six Minutes Walking Test Distance
Time Frame: 1 week after the intervention
|
The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance.
The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
|
1 week after the intervention
|
Muscle Thickness
Time Frame: Before and 1 week after the intervention
|
Ultrasound-derived muscle thickness is measured as the distance between the superficial and deep aponeuroses of the rectus femoris muscle (that is measured half-way along the line from the anterior-superior iliac spine to the superior border of the patella).
Three consecutive static scans of the rectus femoris of both thighs are acquired in the transverse plane and the mean of six measurements (three measurements per side) is considered.
|
Before and 1 week after the intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marco Alessandro Minetto, MD, PhD, University of Turin, Italy
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESC270320
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Pneumonia
-
Ministry of Health, KuwaitUnknownPneumonia, Viral | Moderate COVID-19 Pneumonia, Severe COVID-19 PneumoniaKuwait
-
Institute of Vaccines and Medical Biologicals,...National Institute of Hygiene and Epidemiology, Vietnam; Hanoi Medical University and other collaboratorsCompletedPneumonia, Viral | COVID-19 Vaccine | COVID-19 Disease | SARS PneumoniaVietnam
-
Mahidol UniversityThe Government Pharmaceutical OrganizationCompletedPneumonia, Viral | Covid-19 | SARS Pneumonia | Covid-19 VaccineThailand
-
Patrick RobinsonRecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute BronchitisUnited States
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Fundacion Clinica Valle del LiliUniversidad Autonoma de OccidenteCompletedCOVID-19 Pneumonia | COVID-19 (Coronavirus Disease 2019)Colombia
-
Medical University of LodzRecruitingCOVID-19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionPoland
-
Texas Tech University Health Sciences Center, El...RecruitingPneumonia, Viral | COVID-19 Pneumonia | COVID-19 Respiratory InfectionUnited States
-
Administracion Nacional de Laboratorios e Institutos...RecruitingCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionArgentina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCovid19 | COVID-19 Pneumonia | COVID-19 Respiratory InfectionItaly
Clinical Trials on Neuromuscular Electrical Stimulation
-
Brooks RehabilitationTerminatedBlepharoptosis | LagophthalmosUnited States
-
University Hospital, BrestRecruitingAsthma | Chronic Obstructive Pulmonary Disease Overlap SyndromeFrance
-
Hacettepe UniversityNot yet recruiting
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedStroke | Hemiparesis | FootdropUnited States
-
University of Sao PauloSuspendedRehabilitation | Critical CareBrazil
-
Research Institute for Complex Problems of Cardiovascular...UnknownHeart Failure | Sarcopenia | Peripheral Artery Disease | Exercise IntoleranceRussian Federation
-
Federal University of Rio Grande do SulEnrolling by invitation
-
University of Texas, El PasoRecruitingObesity | Overweight | Insulin ResistanceUnited States
-
University of PittsburghKing Fahad Specialist Hospital Dammam; Saudi Arabian Cultural MissionCompleted